Practo Calls New CPTO Hire ‘Strategic’ While IPO Timeline Stays Vague
Practo hires Global CPTO for IPO preparation but provides no timeline or specific capability gaps addressed by this strategic appointment.
IndiGo’s Strategic Vision Comes from IATA, Not Its Board
IndiGo's incoming CEO Willie Walsh outlines wide-body strategy while still heading IATA, raising questions about board oversight of strategic communication duri
MUFG’s ₹39,618 Crore Investment Gets Board Blessing Without Shareholder Vote
MUFG's ₹39,618 crore investment in Shriram Finance approved by board without shareholder vote despite 20% dilution in India's largest cross-border financial dea
Poonawalla Fincorp’s ₹5,000 Crore QIP Structure Puts Half the Decision Outside Board Control
Poonawalla Fincorp's ₹5,000 crore QIP structure shows how upsize options shift capital decisions from board oversight to market conditions and institutional dem
Bosch’s ₹9,068 Crore Self-Acquisition Raises Capital Allocation Questions
Bosch's ₹9,068 crore acquisition of Bosch Chassis Systems India highlights unique governance challenges in intra-group M&A deals requiring board scrutiny.
Executive Pay Programs Ignore Their Own Warning Systems
Compensation committees create sophisticated executive pay warning systems then routinely ignore their signals, mimicking pilots who override stall alarms.
Five Years Out, Ramraj Cotton Builds IPO-Ready Systems
Ramraj Cotton's five-year IPO preparation focuses on systems and tech infrastructure over growth, creating unique governance planning challenges for extended ti
Demerger Scheme Approval Exposes Board Decision-Making Timeline Gaps
Natco Pharma's demerger approval highlights board decision-making timeline gaps and valuation disclosure issues in corporate restructuring schemes.
Internal CFO Promoted to CEO Role Bypasses External Search Process
AM/NS India promotes CFO Harlalka to CEO role without apparent external search process, raising questions about board nomination committee approach.
Biocon’s CEO Selection Signals Board Confidence in Integration Strategy
Biocon appoints Shreehas Tambe as CEO amid biologics-generics integration. Analysis of board succession planning for complex pharmaceutical business combination